Persistent Eosinophilic Inflammation in Adult Asthmatics with High Serum and Urine Levels of Leukotriene E₄

References

• Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–976. doi:10.1056/NEJMra1608969
   PubMed Web of Science ®Google Scholar
• Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res. 2017;9(1):3–14. doi:10.4168/aair.2017.9.1.3
   PubMed Web of Science ®Google Scholar
• Holgate ST. The sentinel role of the airway epithelium in asthma pathogenesis. Immunol Rev. 2011;242(1):205–219. doi:10.1111/j.1600-065X.2011.01030.x
   PubMed Web of Science ®Google Scholar
• Lee JH, Jung CG, Park HS. An update on the management of aspirin-exacerbated respiratory disease. Expert Rev Respir Med. 2018;12(2):137–143. doi:10.1080/17476348.2018.1417843
   PubMed Web of Science ®Google Scholar
• Ban GY, Cho K, Kim SH, et al. Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2017;47(1):37–47. doi:10.1111/cea.12797
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Parameswaran KN, Watson RM, O’byrne PM. Inhaled leukotriene E4, but not leukotriene D4, increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med. 2001;164(8):1495–1500. doi:10.1164/ajrccm.164.8.2102033
   Web of Science ®Google Scholar
• Green S, Malice M, Tanaka W, Tozzi C, Reiss T. Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax. 2004;59(2):100–104. doi:10.1136/thorax.2003.006825
   PubMed Web of Science ®Google Scholar
• Reiss TF, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB; for the Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med. 1998;158:1213–1220. doi:10.1001/archinte.158.11.1213
   PubMed Web of Science ®Google Scholar
• Hallstrand TS, Henderson WR. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010;10(1):60–66. doi:10.1097/ACI.0b013e32833489c3
   PubMed Web of Science ®Google Scholar
• Bosse Y, Thompson C, McMahon S, Dubois C, Stankova J, Rola‐Pleszczynski M. Leukotriene D4‐induced, epithelial cell‐derived transforming growth factor β1 in human bronchial smooth muscle cell proliferation. Clin Exp Allergy. 2008;38(1):113–121.
   Web of Science ®Google Scholar
• Altraja S, Jaama J, Altraja A. Proteome changes of human bronchial epithelial cells in response to pro-inflammatory mediator leukotriene E4 and pro-remodelling factor TGF-β1. J Proteomics. 2010;73(6):1230–1240. doi:10.1016/j.jprot.2010.02.017
   Web of Science ®Google Scholar
• Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clin Exp Allergy. 2010;40(12):1732–1741. doi:10.1111/j.1365-2222.2010.03630.x
   PubMed Web of Science ®Google Scholar
• Global strategy for asthma management and prevention; 2020 [ cited July 10, 2020]. Available from: http://ginasthma.org/gina-reports/. Accessed October 5, 2021.
   Google Scholar
• Woo SD, Luu QQ, Park HS. NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care. Front Pharmacol. 2020;11:1147. doi:10.3389/fphar.2020.01147
   PubMed Web of Science ®Google Scholar
• Park H. Early and late onset asthmatic responses following lysine‐aspirin inhalation in aspirin‐sensitive asthmatic patients. Clin Exp Allergy. 1995;25(1):38–40. doi:10.1111/j.1365-2222.1995.tb01000.x
   Web of Science ®Google Scholar
• Crimi C, Campisi R, Noto A, et al. Comparability of asthma control test scores between self and physician-administered test. Respir Med. 2020;170:106015. doi:10.1016/j.rmed.2020.106015
   PubMed Web of Science ®Google Scholar
• Juniper EF, Bousquet J, Abetz L, Bateman ED; Goal Committee. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respir Med. 2006;100(4):616–621. doi:10.1016/j.rmed.2005.08.012
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Ban GY, Youn DY, Ye YM, Park HS. Increased expression of serine palmitoyl transferase and ORMDL3 polymorphism are associated with eosinophilic inflammation and airflow limitation in aspirin-exacerbated respiratory disease. PLoS One. 2020;15(10):e0240334. doi:10.1371/journal.pone.0240334
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med. 2007;357(18):1841–1854. doi:10.1056/NEJMra071371
   PubMed Web of Science ®Google Scholar
• Sandrini A, Ferreira IM, Gutierrez C, Jardim JR, Zamel N, Chapman KR. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest. 2003;124(4):1334–1340. doi:10.1378/chest.124.4.1334
   PubMed Web of Science ®Google Scholar
• Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol. 2004;92(6):641–648. doi:10.1016/S1081-1206(10)61430-5
   PubMed Web of Science ®Google Scholar
• Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 1999;160(6):1862–1868. doi:10.1164/ajrccm.160.6.9803042
   PubMed Web of Science ®Google Scholar
• Cai C, Yang J, Hu S, Zhou M, Guo W. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung. 2007;185(2):105–112. doi:10.1007/s00408-006-0001-8
   PubMed Web of Science ®Google Scholar
• Espinosa K, Bossé Y, Stankova J, Rola-Pleszczynski M. CysLT1 receptor upregulation by TGF-β and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol. 2003;111(5):1032–1040. doi:10.1067/mai.2003.1451
   Web of Science ®Google Scholar
• Baptista-dos-Reis R, Muniz VS, Neves JS. Multifaceted roles of cysteinyl leukotrienes in eliciting eosinophil granule protein secretion. Biomed Res Int. 2015;2015:848762. doi:10.1155/2015/848762
   Web of Science ®Google Scholar
• Lund SJ, Portillo A, Cavagnero K, et al. Leukotriene C4 potentiates IL-33–induced group 2 innate lymphoid cell activation and lung inflammation. J Immunol. 2017;199(3):1096–1104. doi:10.4049/jimmunol.1601569
   Web of Science ®Google Scholar
• Liu T, Barrett NA, Kanaoka Y, et al. Type 2 cysteinyl leukotriene receptors drive IL-33–dependent type 2 immunopathology and aspirin sensitivity. J Immunol. 2018;200(3):915–927. doi:10.4049/jimmunol.1700603
   Web of Science ®Google Scholar
• Jonckheere AC, Bullens DM, Seys SF. Innate lymphoid cells in asthma: pathophysiological insights from murine models to human asthma phenotypes. Curr Opin Allergy Clin Immunol. 2019;19(1):53–60. doi:10.1097/ACI.0000000000000497
   Web of Science ®Google Scholar
• Buchheit KM, Laidlaw TM. Update on the management of aspirin-exacerbated respiratory disease. Allergy Asthma Immunol Res. 2016;8(4):298. doi:10.4168/aair.2016.8.4.298
   PubMed Web of Science ®Google Scholar
• Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med. 2009;206(11):2543–2555. doi:10.1084/jem.20091240
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Boyce JA. Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy. 2012;42(9):1313–1320. doi:10.1111/j.1365-2222.2012.03982.x
   PubMed Web of Science ®Google Scholar
• Choi Y, Lee Y, Park HS. Which factors associated with activated eosinophils contribute to the pathogenesis of aspirin-exacerbated respiratory disease? Allergy Asthma Immunol Res. 2019;11(3):320. doi:10.4168/aair.2019.11.3.320
   PubMed Web of Science ®Google Scholar